Neurosense Therapeutics Stock Performance
| NRSN Stock | USD 0.96 0.02 2.13% |
The company secures a Beta (Market Risk) of 0.0234, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Neurosense Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Neurosense Therapeutics is expected to be smaller as well. At this point, Neurosense Therapeutics has a negative expected return of -0.0315%. Please make sure to verify Neurosense Therapeutics' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Neurosense Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Neurosense Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Neurosense Therapeutics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 2.6 M | |
| Total Cashflows From Investing Activities | 1000.00 |
Neurosense | Build AI portfolio with Neurosense Stock |
Neurosense Therapeutics Relative Risk vs. Return Landscape
If you would invest 110.00 in Neurosense Therapeutics on October 28, 2025 and sell it today you would lose (14.00) from holding Neurosense Therapeutics or give up 12.73% of portfolio value over 90 days. Neurosense Therapeutics is currently does not generate positive expected returns and assumes 6.3128% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Neurosense, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurosense Therapeutics Target Price Odds to finish over Current Price
The tendency of Neurosense Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.96 | 90 days | 0.96 | about 56.11 |
Based on a normal probability distribution, the odds of Neurosense Therapeutics to move above the current price in 90 days from now is about 56.11 (This Neurosense Therapeutics probability density function shows the probability of Neurosense Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Neurosense Therapeutics has a beta of 0.0234. This indicates as returns on the market go up, Neurosense Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Neurosense Therapeutics will be expected to be much smaller as well. Additionally Neurosense Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Neurosense Therapeutics Price Density |
| Price |
Predictive Modules for Neurosense Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Neurosense Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Neurosense Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Neurosense Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Neurosense Therapeutics is not an exception. The market had few large corrections towards the Neurosense Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Neurosense Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Neurosense Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.04 | |
β | Beta against Dow Jones | 0.02 | |
σ | Overall volatility | 0.13 | |
Ir | Information ratio | -0.02 |
Neurosense Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Neurosense Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Neurosense Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Neurosense Therapeutics generated a negative expected return over the last 90 days | |
| Neurosense Therapeutics has high historical volatility and very poor performance | |
| Neurosense Therapeutics has some characteristics of a very speculative penny stock | |
| Neurosense Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (10.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurosense Therapeutics currently holds about 10.37 M in cash with (10.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Roughly 26.0% of the company outstanding shares are owned by corporate insiders |
Neurosense Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Neurosense Stock often depends not only on the future outlook of the current and potential Neurosense Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Neurosense Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 18.6 M | |
| Cash And Short Term Investments | 3.4 M |
Neurosense Therapeutics Fundamentals Growth
Neurosense Stock prices reflect investors' perceptions of the future prospects and financial health of Neurosense Therapeutics, and Neurosense Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurosense Stock performance.
| Return On Equity | -24.78 | |||
| Return On Asset | -3.04 | |||
| Current Valuation | 25.18 M | |||
| Shares Outstanding | 29.55 M | |||
| Price To Book | 12.82 X | |||
| EBITDA | (9.88 M) | |||
| Cash And Equivalents | 10.37 M | |||
| Cash Per Share | 0.89 X | |||
| Total Debt | 73 K | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (10.13 M) | |||
| Earnings Per Share | (0.36) X | |||
| Total Asset | 4.58 M | |||
| Retained Earnings | (36.66 M) | |||
About Neurosense Therapeutics Performance
By examining Neurosense Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Neurosense Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Neurosense Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Neurosense Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.Things to note about Neurosense Therapeutics performance evaluation
Checking the ongoing alerts about Neurosense Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurosense Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurosense Therapeutics generated a negative expected return over the last 90 days | |
| Neurosense Therapeutics has high historical volatility and very poor performance | |
| Neurosense Therapeutics has some characteristics of a very speculative penny stock | |
| Neurosense Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (10.21 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurosense Therapeutics currently holds about 10.37 M in cash with (10.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Roughly 26.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Neurosense Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurosense Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Neurosense Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurosense Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurosense Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurosense Therapeutics' stock. These opinions can provide insight into Neurosense Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.